Cell and Tissue Preservation Market (By Type: Cell, Tissue; By Application: Therapeutics, Drug Discovery, Gene therapy, IVF treatment, Cell therapy, Research & Development; By Product: Equipment, Software, Bio-preservation Media; By End User: Biobanks, Hospitals; By Cell Provider: CD34+, CD19+, MSC, iPSC, hESC, Tumor Cells, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024 – 2033
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Cell and Tissue Preservation Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Cell and Tissue Preservation Market, by Type, 2024-2033
8.1.1. Cell
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Tissue
8.1.2.1. Market Revenue and Forecast (2021-2033)
9.1. Cell and Tissue Preservation Market, by Application Type, 2024-2033
9.1.1. Therapeutics
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Drug Discovery
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Gene therapy
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. IVF treatment
9.1.4.1. Market Revenue and Forecast (2021-2033)
9.1.5. Research & Development
9.1.5.1. Market Revenue and Forecast (2021-2033)
9.1.6. Cell therapy
9.1.6.1. Market Revenue and Forecast (2021-2033)
10.1. Cell and Tissue Preservation Market, by Product Type, 2024-2033
10.1.1. Equipment
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Software
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Bio-preservation Media
10.1.3.1. Market Revenue and Forecast (2021-2033)
11.1. Cell and Tissue Preservation Market, by End User Type, 2024-2033
11.1.1. Biobanks
11.1.1.1. Market Revenue and Forecast (2021-2033)
11.1.2. Hospitals
11.1.2.1. Market Revenue and Forecast (2021-2033)
12.1. Cell and Tissue Preservation Market, by Cell Provider, 2024-2033
12.1.1. CD34+
12.1.1.1. Market Revenue and Forecast (2021-2033)
12.1.2. CD19+
12.1.2.1. Market Revenue and Forecast (2021-2033)
12.1.3. MSC
12.1.3.1. Market Revenue and Forecast (2021-2033)
12.1.4. iPSC
12.1.4.1. Market Revenue and Forecast (2021-2033)
12.1.5. hESC
12.1.5.1. Market Revenue and Forecast (2021-2033)
12.1.6. Tumor Cells
12.1.6.1. Market Revenue and Forecast (2021-2033)
12.1.7. Others
12.1.7.1. Market Revenue and Forecast (2021-2033)
13.1. North America
13.1.1. Market Revenue and Forecast, by Type (2021-2033)
13.1.2. Market Revenue and Forecast, by Application (2021-2033)
13.1.3. Market Revenue and Forecast, by Product (2021-2033)
13.1.4. Market Revenue and Forecast, by End User (2021-2033)
13.1.5. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Type (2021-2033)
13.1.6.2. Market Revenue and Forecast, by Application (2021-2033)
13.1.6.3. Market Revenue and Forecast, by Product (2021-2033)
13.1.6.4. Market Revenue and Forecast, by End User (2021-2033)
13.1.7. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.1.8. Rest of North America
13.1.8.1. Market Revenue and Forecast, by Type (2021-2033)
13.1.8.2. Market Revenue and Forecast, by Application (2021-2033)
13.1.8.3. Market Revenue and Forecast, by Product (2021-2033)
13.1.8.4. Market Revenue and Forecast, by End User (2021-2033)
13.1.8.5. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Type (2021-2033)
13.2.2. Market Revenue and Forecast, by Application (2021-2033)
13.2.3. Market Revenue and Forecast, by Product (2021-2033)
13.2.4. Market Revenue and Forecast, by End User (2021-2033)
13.2.5. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Type (2021-2033)
13.2.6.2. Market Revenue and Forecast, by Application (2021-2033)
13.2.6.3. Market Revenue and Forecast, by Product (2021-2033)
13.2.7. Market Revenue and Forecast, by End User (2021-2033)
13.2.8. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Type (2021-2033)
13.2.9.2. Market Revenue and Forecast, by Application (2021-2033)
13.2.9.3. Market Revenue and Forecast, by Product (2021-2033)
13.2.10. Market Revenue and Forecast, by End User (2021-2033)
13.2.11. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Type (2021-2033)
13.2.12.2. Market Revenue and Forecast, by Application (2021-2033)
13.2.12.3. Market Revenue and Forecast, by Product (2021-2033)
13.2.12.4. Market Revenue and Forecast, by End User (2021-2033)
13.2.13. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Type (2021-2033)
13.2.14.2. Market Revenue and Forecast, by Application (2021-2033)
13.2.14.3. Market Revenue and Forecast, by Product (2021-2033)
13.2.14.4. Market Revenue and Forecast, by End User (2021-2033)
13.2.15. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Type (2021-2033)
13.3.2. Market Revenue and Forecast, by Application (2021-2033)
13.3.3. Market Revenue and Forecast, by Product (2021-2033)
13.3.4. Market Revenue and Forecast, by End User (2021-2033)
13.3.5. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Type (2021-2033)
13.3.6.2. Market Revenue and Forecast, by Application (2021-2033)
13.3.6.3. Market Revenue and Forecast, by Product (2021-2033)
13.3.6.4. Market Revenue and Forecast, by End User (2021-2033)
13.3.7. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Type (2021-2033)
13.3.8.2. Market Revenue and Forecast, by Application (2021-2033)
13.3.8.3. Market Revenue and Forecast, by Product (2021-2033)
13.3.8.4. Market Revenue and Forecast, by End User (2021-2033)
13.3.9. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Type (2021-2033)
13.3.10.2. Market Revenue and Forecast, by Application (2021-2033)
13.3.10.3. Market Revenue and Forecast, by Product (2021-2033)
13.3.10.4. Market Revenue and Forecast, by End User (2021-2033)
13.3.10.5. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Type (2021-2033)
13.3.11.2. Market Revenue and Forecast, by Application (2021-2033)
13.3.11.3. Market Revenue and Forecast, by Product (2021-2033)
13.3.11.4. Market Revenue and Forecast, by End User (2021-2033)
13.3.11.5. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Type (2021-2033)
13.4.2. Market Revenue and Forecast, by Application (2021-2033)
13.4.3. Market Revenue and Forecast, by Product (2021-2033)
13.4.4. Market Revenue and Forecast, by End User (2021-2033)
13.4.5. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Type (2021-2033)
13.4.6.2. Market Revenue and Forecast, by Application (2021-2033)
13.4.6.3. Market Revenue and Forecast, by Product (2021-2033)
13.4.6.4. Market Revenue and Forecast, by End User (2021-2033)
13.4.7. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Type (2021-2033)
13.4.8.2. Market Revenue and Forecast, by Application (2021-2033)
13.4.8.3. Market Revenue and Forecast, by Product (2021-2033)
13.4.8.4. Market Revenue and Forecast, by End User (2021-2033)
13.4.9. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Type (2021-2033)
13.4.10.2. Market Revenue and Forecast, by Application (2021-2033)
13.4.10.3. Market Revenue and Forecast, by Product (2021-2033)
13.4.10.4. Market Revenue and Forecast, by End User (2021-2033)
13.4.10.5. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Type (2021-2033)
13.4.11.2. Market Revenue and Forecast, by Application (2021-2033)
13.4.11.3. Market Revenue and Forecast, by Product (2021-2033)
13.4.11.4. Market Revenue and Forecast, by End User (2021-2033)
13.4.11.5. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Type (2021-2033)
13.5.2. Market Revenue and Forecast, by Application (2021-2033)
13.5.3. Market Revenue and Forecast, by Product (2021-2033)
13.5.4. Market Revenue and Forecast, by End User (2021-2033)
13.5.5. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Type (2021-2033)
13.5.6.2. Market Revenue and Forecast, by Application (2021-2033)
13.5.6.3. Market Revenue and Forecast, by Product (2021-2033)
13.5.6.4. Market Revenue and Forecast, by End User (2021-2033)
13.5.7. Market Revenue and Forecast, by Cell Provider (2021-2033)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Type (2021-2033)
13.5.8.2. Market Revenue and Forecast, by Application (2021-2033)
13.5.8.3. Market Revenue and Forecast, by Product (2021-2033)
13.5.8.4. Market Revenue and Forecast, by End User (2021-2033)
13.5.8.5. Market Revenue and Forecast, by Cell Provider (2021-2033)
14.1. Thermo Fisher Scientific, Inc.
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Lonza
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. BD
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. MerckKGaA
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Cytiva
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Agilent Technologies, Inc.
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Avantor, Inc.
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. FUJIFILM Irvine Scientific
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. BioLifeSolutions Inc.
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. AMSBIO
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
14.11. Princeton CryoTech
14.11.1. Company Overview
14.11.2. Product Offerings
14.11.3. Financial Performance
14.11.4. Recent Initiatives
14.12. STEMCELL Technologies Inc.
14.12.1. Company Overview
14.12.2. Product Offerings
14.12.3. Financial Performance
14.12.4. Recent Initiatives
14.13. LGC SeraCare
14.13.1. Company Overview
14.13.2. Product Offerings
14.13.3. Financial Performance
14.13.4. Recent Initiatives
14.14. Corning Incorporated
14.14.1. Company Overview
14.14.2. Product Offerings
14.14.3. Financial Performance
14.14.4. Recent Initiatives
14.15. CellGenix GmbH
14.15.1. Company Overview
14.15.2. Product Offerings
14.15.3. Financial Performance
14.15.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client